AI assistant
IONIS PHARMACEUTICALS INC — Director's Dealing 2012
Jan 3, 2012
30591_dirs_2012-01-03_084d2e3f-39ac-48bf-8e13-67fad69afb99.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ISIS PHARMACEUTICALS INC (ISIS)
CIK: 0000874015
Period of Report: 2011-12-01
Reporting Person: BENNETT C FRANK (Senior Vice President)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2011-12-01 | Common Stock | J | 324 | $6.1285 | Acquired | 629 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2012-01-03 | Employee Stock Option (right to buy) | $7.25 | A | 25013 | Acquired | 2022-01-02 | Common Stock (25013) | Direct |
Footnotes
F1: Reporting 324 shares acquired under the Isis Pharmaceuticals, Inc. Amended and Restated 2000 Employee Stock Purchase Plan on January 1, 2012. These 324 shares may not be sold until July 2, 2012.
F2: Grant of 1/3/12 to reporting person of stock options under the Isis Pharmaceuticals, Inc. 1989 Stock Option Plan. 25% of the shares subject to the option will vest and become exercisable on 1/3/13. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 6,253 shares per year. The option is exercisable as to 0 shares on 1/3/12.